The 23-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC) provides the clearest evidence yet that sustained PSA testing according to protocol can lower prostate cancer mortality and improve the benefit-to-harm balance of screening.

Published in The New England Journal of Medicine (Roobol et al., 2025), the trial enrolled more than 162,000 men aged 55-69 years across eight European countries. Participants were randomly assigned either to regular PSA testing or to a control group without screening invitations.

After a median follow-up of 23 years, the study found a 13% reduction in prostate cancer mortality among men invited for PSA screening. This is equivalent to one prostate cancer death prevented for every 456 men screened, underscoring a durable survival benefit that strengthens with longer follow-up.

The findings support a shift toward risk-based, patient-centered screening strategies. They suggest that thoughtfully implemented PSA testing— particularly when tailored to individual risk profiles — can bring meaningful reductions in mortality while minimising overdiagnosis and overtreatment.

Read the article here.

A new nine-year study shows that the Stockholm3 blood test can detect aggressive prostate cancers that standard PSA tests often miss. Men with PSA 1.5–3 ng/mL but a positive Stockholm3 were nine times more likely to experience high-risk recurrence after treatment than men with higher PSA but negative Stockholm3. The test also helps avoid unnecessary biopsies in men with high PSA but low risk scores.

Read more here.

Researchers have identified TRβ as a key driver of prostate cancer growth. A new study found that selective inhibitor NH‑3 reduced tumour growth in lab and mouse models by disrupting both TRβ and androgen receptor pathways. TRβ is elevated in patient tumours, highlighting its potential as a promising new therapy avenue.

Read the article here.

The National Alliance of State Prostate Cancer Coalitions in the United States has launched a Prostatepedia dedicated to radiation therapy. Three US specialists give an overview of what is new and improving in radiation oncology in the treatment of prostate cancer and how patients can benefit. Two patients also share their own experiences with radiation therapy.

The Board of Europa Uomo convened in Barcelona on 29-30 October for a Board Retreat dedicated to shaping the organisation’s strategic plan for the next three years.

Under the skilled facilitation of Nicola Bedlington, the Board engaged in open and constructive discussions covering Europa Uomo’s vision, mission, strategic goals, activity roadmap, governance and the strengthening of the Secretariat’s capacity.

A first draft of the new strategic document will be delivered by the end of November 2025.

A key outcome of the retreat was the decision to establish a number of committees to support the Board’s work and enhance operational focus across different areas:

• Executive Board – Led by Erik Briers, Chairman Europa Uomo

• Legal and Membership Committee – Led by Igor Antauer, Secretary Europa Uomo

• Finance Committee – Led by Marko Koivuneva, Treasurer Europa Uomo

• Scientific Committee – Led by Kees Vos, First Vice-Chairman Europa Uomo

• Europa Uomo Academy Committee – Led by Bo Madsen, Board Member Europa Uomo

• Awareness and Runs Committee – Led by Marko Koivuneva

• Mental Health Committee – Led by Tania Estapé, Board Member Europa Uomo

• Communication Committee – Led by Simon Crompton, Communication Advisor

Europa Uomo members and Summer School alumni have been invited to join these committees and contribute to the implementation of the strategic plan.

Thank you to Bayer for producing this great little film about our Step Out for Prostate Cancer run in Berlin – and thank you again to all of those people who participated and helped raise awareness of prostate cancer.

Please join our efforts – register at bit.ly/4gF0do9 and run or walk in your own time before the end of November to raise money and awareness!

On 2nd November the Panhellenic Association for Prostate Cancer (Europa Uomo Hellas) organised an information event entitled “Prostate Cancer – The Importance of Early Diagnosis” at Villa Zografou. The event, supported by the Municipality of Zografou and under the auspices of the Hellenic Urological Association, HeSMO, and ELL.O.K., emphasised the crucial role of awareness, prevention, and early screening.

Experts including Andreas Skolarikos, George Pissakas and Aristotelis Bamias discussed diagnosis, modern treatments and the impact on patients’ daily lives. Dimitris Deligiannidis, President of Europa Uomo Hellas, shared a patient’s journey while psychologist Nestor Tzalidis and nutrition specialist Panagiota Mitrou highlighted the importance of emotional support and proper nutrition.

The event underscored that prostate cancer often presents no early symptoms, yet early diagnosis can increase survival rates to over 98%. Attendees were reminded that regular screening is essential, making prevention the most effective act of care for men and their families.

As Dimitris Deligiannidis noted: “Prostate cancer is highly treatable if diagnosed in time. Prevention and regular screening are not optional — they are vital.”

The full event is available for viewing on YouTube here.

For decades, the transrectal (TRUS) biopsy approach was the standard for detecting prostate cancer. But new randomised studies suggest the transperineal (TP) method — performed through the skin between the scrotum and anus rather than via the rectum—may offer key advantages in both safety and accuracy.

Therefore Active Surveillance Patients International is organising a roundtable on transperineal vs transrectal biospies on 22 November.

Register here.

The OnHOME Alliance has developed a patient survey to achieve greater understanding about the issues related to an online prescription service. The survey is available in 24 languages and will close on 20 November, 2025.